11.25 USD
-0.27 (-2.34%)
11.2309 USD
-0.02 (-0.17%)
Overall XRAY gets a fundamental rating of 4 out of 10. We evaluated XRAY against 186 industry peers in the Health Care Equipment & Supplies industry. There are concerns on the financial health of XRAY while its profitability can be described as average. XRAY is valued quite cheap, but it does not seem to be growing. Finally XRAY also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
In the past year XRAY was profitable.
XRAY had a positive operating cash flow in the past year.
In the past 5 years XRAY reported 4 times negative net income.
XRAY had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -15.60%, XRAY is in line with its industry, outperforming 56.45% of the companies in the same industry.
Looking at the Return On Equity, with a value of -59.68%, XRAY is in line with its industry, outperforming 47.85% of the companies in the same industry.
Looking at the Return On Invested Capital, with a value of 5.04%, XRAY is in the better half of the industry, outperforming 76.34% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for XRAY is below the industry average of 8.84%.
The last Return On Invested Capital (5.04%) for XRAY is above the 3 year average (4.11%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROIC | 5.04% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
1.3 Margins
XRAY has a better Operating Margin (7.48%) than 74.19% of its industry peers.
XRAY's Operating Margin has declined in the last couple of years.
The Gross Margin of XRAY (51.10%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of XRAY has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% |
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is below the Cost of Capital (WACC), so XRAY is destroying value.
The number of shares outstanding for XRAY has been reduced compared to 1 year ago.
XRAY has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, XRAY has a worse debt to assets ratio.
2.2 Solvency
XRAY has an Altman-Z score of 0.93. This is a bad value and indicates that XRAY is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.93, XRAY is in line with its industry, outperforming 50.00% of the companies in the same industry.
XRAY has a debt to FCF ratio of 29.94. This is a negative value and a sign of low solvency as XRAY would need 29.94 years to pay back of all of its debts.
The Debt to FCF ratio of XRAY (29.94) is better than 68.82% of its industry peers.
XRAY has a Debt/Equity ratio of 1.36. This is a high value indicating a heavy dependency on external financing.
XRAY has a Debt to Equity ratio of 1.36. This is in the lower half of the industry: XRAY underperforms 79.03% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Altman-Z | 0.93 |
ROIC/WACC0.82
WACC6.15%
2.3 Liquidity
XRAY has a Current Ratio of 1.47. This is a normal value and indicates that XRAY is financially healthy and should not expect problems in meeting its short term obligations.
XRAY has a Current ratio of 1.47. This is in the lower half of the industry: XRAY underperforms 75.27% of its industry peers.
A Quick Ratio of 0.99 indicates that XRAY may have some problems paying its short term obligations.
The Quick ratio of XRAY (0.99) is worse than 75.81% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
The earnings per share for XRAY have decreased strongly by -14.59% in the last year.
The Earnings Per Share has been decreasing by -7.38% on average over the past years.
Looking at the last year, XRAY shows a decrease in Revenue. The Revenue has decreased by -7.08% in the last year.
Measured over the past years, XRAY shows a decrease in Revenue. The Revenue has been decreasing by -1.17% on average per year.
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
3.2 Future
XRAY is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 7.40% yearly.
XRAY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.34% yearly.
EPS Next Y-2.07%
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
EPS Next 5Y7.4%
Revenue Next Year-4.33%
Revenue Next 2Y-1.82%
Revenue Next 3Y-0.42%
Revenue Next 5Y1.34%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 7.12 indicates a rather cheap valuation of XRAY.
Compared to the rest of the industry, the Price/Earnings ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 97.31% of the companies listed in the same industry.
The average S&P500 Price/Earnings ratio is at 26.84. XRAY is valued rather cheaply when compared to this.
The Price/Forward Earnings ratio is 7.04, which indicates a rather cheap valuation of XRAY.
Based on the Price/Forward Earnings ratio, XRAY is valued cheaper than 98.92% of the companies in the same industry.
The average S&P500 Price/Forward Earnings ratio is at 23.40. XRAY is valued rather cheaply when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.12 | ||
| Fwd PE | 7.04 |
4.2 Price Multiples
XRAY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. XRAY is cheaper than 96.24% of the companies in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of XRAY indicates a rather cheap valuation: XRAY is cheaper than 80.11% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 28.06 | ||
| EV/EBITDA | 7.01 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
5. Dividend
5.1 Amount
XRAY has a Yearly Dividend Yield of 4.91%, which is a nice return.
XRAY's Dividend Yield is rather good when compared to the industry average which is at 0.20. XRAY pays more dividend than 99.46% of the companies in the same industry.
Compared to an average S&P500 Dividend Yield of 2.00, XRAY pays a better dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.91% |
5.2 History
The dividend of XRAY is nicely growing with an annual growth rate of 11.21%!
XRAY has been paying a dividend for at least 10 years, so it has a reliable track record.
XRAY has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)11.21%
Div Incr Years6
Div Non Decr Years30
5.3 Sustainability
The earnings of XRAY are negative and hence is the payout ratio. XRAY will probably not be able to sustain this dividend level.
XRAY's earnings are growing slower than its dividend. This means the dividend growth is not sustainable.
DP-14.4%
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
11.25
-0.27 (-2.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners107.05%
Inst Owner Change9.76%
Ins Owners0.29%
Ins Owner Change-3.01%
Market Cap2.24B
Revenue(TTM)3.62B
Net Income(TTM)-882.00M
Analysts69.52
Price Target12.79 (13.69%)
Short Float %7.14%
Short Ratio3.87
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.91% |
Yearly Dividend0.62
Dividend Growth(5Y)11.21%
DP-14.4%
Div Incr Years6
Div Non Decr Years30
Ex-Date
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-8.77%
Min EPS beat(2)-19.03%
Max EPS beat(2)1.49%
EPS beat(4)2
Avg EPS beat(4)-3.17%
Min EPS beat(4)-40.52%
Max EPS beat(4)45.37%
EPS beat(8)3
Avg EPS beat(8)-1.68%
EPS beat(12)6
Avg EPS beat(12)4.59%
EPS beat(16)7
Avg EPS beat(16)1.99%
Revenue beat(2)0
Avg Revenue beat(2)-1.42%
Min Revenue beat(2)-1.67%
Max Revenue beat(2)-1.16%
Revenue beat(4)1
Avg Revenue beat(4)-1.42%
Min Revenue beat(4)-3.62%
Max Revenue beat(4)0.77%
Revenue beat(8)2
Avg Revenue beat(8)-1.44%
Revenue beat(12)5
Avg Revenue beat(12)-0.9%
Revenue beat(16)5
Avg Revenue beat(16)-2.02%
PT rev (1m)-1.53%
PT rev (3m)-25.35%
EPS NQ rev (1m)-0.64%
EPS NQ rev (3m)-42.56%
EPS NY rev (1m)-14.63%
EPS NY rev (3m)-15.02%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.3%
Revenue NY rev (1m)-0.27%
Revenue NY rev (3m)-0.32%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 7.12 | ||
| Fwd PE | 7.04 | ||
| P/S | 0.62 | ||
| P/FCF | 28.06 | ||
| P/OCF | 10.16 | ||
| P/B | 1.52 | ||
| P/tB | N/A | ||
| EV/EBITDA | 7.01 |
EPS(TTM)1.58
EY14.04%
EPS(NY)1.6
Fwd EY14.21%
FCF(TTM)0.4
FCFY3.56%
OCF(TTM)1.11
OCFY9.84%
SpS18.16
BVpS7.41
TBVpS-4.29
PEG (NY)N/A
PEG (5Y)N/A
Graham Number16.23
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -15.6% | ||
| ROE | -59.68% | ||
| ROCE | 6.38% | ||
| ROIC | 5.04% | ||
| ROICexc | 5.51% | ||
| ROICexgc | 13.81% | ||
| OM | 7.48% | ||
| PM (TTM) | N/A | ||
| GM | 51.1% | ||
| FCFM | 2.21% |
ROA(3y)-10.01%
ROA(5y)-5.27%
ROE(3y)-25.27%
ROE(5y)-13.81%
ROIC(3y)4.11%
ROIC(5y)4.26%
ROICexc(3y)4.36%
ROICexc(5y)4.5%
ROICexgc(3y)15.64%
ROICexgc(5y)20.94%
ROCE(3y)5.38%
ROCE(5y)5.49%
ROICexgc growth 3Y-31.16%
ROICexgc growth 5Y-12.42%
ROICexc growth 3Y-13.44%
ROICexc growth 5Y-4.44%
OM growth 3Y-25.8%
OM growth 5Y-12.74%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.16%
GM growth 5Y-0.95%
F-Score4
Asset Turnover0.64
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.36 | ||
| Debt/FCF | 29.94 | ||
| Debt/EBITDA | 3.26 | ||
| Cap/Depr | 40.63% | ||
| Cap/Sales | 3.89% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 35.76% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.47 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | 0.93 |
F-Score4
WACC6.15%
ROIC/WACC0.82
Cap/Depr(3y)46.81%
Cap/Depr(5y)41.51%
Cap/Sales(3y)4.1%
Cap/Sales(5y)3.65%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.59%
EPS 3Y-16.51%
EPS 5Y-7.38%
EPS Q2Q%-26%
EPS Next Y-2.07%
EPS Next 2Y-2.16%
EPS Next 3Y2.63%
EPS Next 5Y7.4%
Revenue 1Y (TTM)-7.08%
Revenue growth 3Y-3.58%
Revenue growth 5Y-1.17%
Sales Q2Q%-4.94%
Revenue Next Year-4.33%
Revenue Next 2Y-1.82%
Revenue Next 3Y-0.42%
Revenue Next 5Y1.34%
EBIT growth 1Y3.04%
EBIT growth 3Y-28.45%
EBIT growth 5Y-13.75%
EBIT Next Year42.44%
EBIT Next 3Y14.41%
EBIT Next 5Y11.96%
FCF growth 1Y-63.3%
FCF growth 3Y-18.29%
FCF growth 5Y-11.45%
OCF growth 1Y-38.44%
OCF growth 3Y-11.14%
OCF growth 5Y-6.32%
DENTSPLY SIRONA INC / XRAY FAQ
Can you provide the ChartMill fundamental rating for DENTSPLY SIRONA INC?
ChartMill assigns a fundamental rating of 4 / 10 to XRAY.
Can you provide the valuation status for DENTSPLY SIRONA INC?
ChartMill assigns a valuation rating of 7 / 10 to DENTSPLY SIRONA INC (XRAY). This can be considered as Undervalued.
How profitable is DENTSPLY SIRONA INC (XRAY) stock?
DENTSPLY SIRONA INC (XRAY) has a profitability rating of 4 / 10.
What is the valuation of DENTSPLY SIRONA INC based on its PE and PB ratios?
The Price/Earnings (PE) ratio for DENTSPLY SIRONA INC (XRAY) is 7.12 and the Price/Book (PB) ratio is 1.52.
How sustainable is the dividend of DENTSPLY SIRONA INC (XRAY) stock?
The dividend rating of DENTSPLY SIRONA INC (XRAY) is 7 / 10 and the dividend payout ratio is -14.4%.